- Home
- ACON vs TCRT Comparison
ACON vs TCRT Comparison
Compare ACON & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- TCRT
- Stock Information
- Founded
- ACON 2008
- TCRT 1998
- Country
- ACON United States
- TCRT United States
- Employees
- ACON N/A
- TCRT N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- TCRT Health Care
- Exchange
- ACON Nasdaq
- TCRT Nasdaq
- Market Cap
- ACON 4.2M
- TCRT 3.8M
- IPO Year
- ACON 2022
- TCRT N/A
- Fundamental
- Price
- ACON $7.28
- TCRT $5.02
- Analyst Decision
- ACON Buy
- TCRT
- Analyst Count
- ACON 2
- TCRT 0
- Target Price
- ACON $481.00
- TCRT N/A
- AVG Volume (30 Days)
- ACON 15.5K
- TCRT 45.5K
- Earning Date
- ACON 08-13-2025
- TCRT 08-13-2025
- Dividend Yield
- ACON N/A
- TCRT N/A
- EPS Growth
- ACON N/A
- TCRT N/A
- EPS
- ACON N/A
- TCRT N/A
- Revenue
- ACON $54,601.00
- TCRT $11,000.00
- Revenue This Year
- ACON $212.31
- TCRT $5,680,500.00
- Revenue Next Year
- ACON $92.86
- TCRT N/A
- P/E Ratio
- ACON N/A
- TCRT N/A
- Revenue Growth
- ACON N/A
- TCRT 83.33
- 52 Week Low
- ACON $6.20
- TCRT $1.31
- 52 Week High
- ACON $3,499.51
- TCRT $7.40
- Technical
- Relative Strength Index (RSI)
- ACON 42.96
- TCRT 76.09
- Support Level
- ACON $6.79
- TCRT $3.00
- Resistance Level
- ACON $7.29
- TCRT $4.92
- Average True Range (ATR)
- ACON 0.37
- TCRT 0.63
- MACD
- ACON 0.31
- TCRT 0.18
- Stochastic Oscillator
- ACON 45.79
- TCRT 98.55
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.